Identification of p38 beta as a therapeutic target for the treatment of Sézary Syndrome

ABSTRACT: Cutaneous T-Cell Lymphomas (CTCL) represent a group of hematopoietic malignancies that home to the skin and have no known molecular basis for disease pathogenesis. Sézary syndrome (SS) is the leukemic variant of CTCL. Currently, CTCL is incurable, highlighting the need for new therapeutic modalities. We have previously observed that combined small-molecule inhibition of protein kinase C (PKC) β and glycogen synthase kinase 3 (GSK3) causes synergistic apoptosis in CTCL cell lines and patient cells. Through microarray analysis of a SS cell line, we surveyed global gene expression following combined PKCβ-GSK3 treatment to elucidate therapeutic targets responsible for cell death. Clinically relevant targets were defined as genes differentially expressed in SS patients that were modulated by

ORGANISM(S): Homo sapiens

SUBMITTER: Chunfa Jie 

PROVIDER: E-GEOD-59179 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress